These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15347910)

  • 21. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
    Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
    Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
    di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
    Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic myeloablative transplantation for patients aged 50 years and over.
    Yanada M; Emi N; Naoe T; Sakamaki H; Iseki T; Hirabayashi N; Karasuno T; Chiba S; Atsuta Y; Hamajima N; Takahashi S; Kato S
    Bone Marrow Transplant; 2004 Jul; 34(1):29-35. PubMed ID: 15156161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
    El Kourashy S; Williamson T; Chaudhry MA; Savoie ML; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Yang M; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA; Russell JA
    Bone Marrow Transplant; 2011 Aug; 46(8):1077-83. PubMed ID: 21057555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
    Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
    Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.
    Schmid I; Stachel D; Pagel P; Albert MH
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):438-44. PubMed ID: 18342786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
    Corker E; Astwood E; Williams J; Vora A
    Br J Haematol; 2012 Oct; 159(1):104-6. PubMed ID: 22804487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.